Shanghai Haohai Biological Technology Co Ltd banner

Shanghai Haohai Biological Technology Co Ltd
SSE:688366

Watchlist Manager
Shanghai Haohai Biological Technology Co Ltd Logo
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Watchlist
Price: 38.8 CNY -0.18% Market Closed
Market Cap: ¥8.9B

Shanghai Haohai Biological Technology Co Ltd
Other Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Shanghai Haohai Biological Technology Co Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Other Receivables
¥85.9m
CAGR 3-Years
23%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Receivables
¥382.3m
CAGR 3-Years
-5%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Receivables
¥0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
RemeGen Co Ltd
SSE:688331
Other Receivables
¥383.4m
CAGR 3-Years
56%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Other Receivables
¥0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Other Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai Haohai Biological Technology Co Ltd
Glance View

Market Cap
8.9B CNY
Industry
Biotechnology

Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.

Intrinsic Value
55.24 CNY
Undervaluation 30%
Intrinsic Value
Price ¥38.8

See Also

What is Shanghai Haohai Biological Technology Co Ltd's Other Receivables?
Other Receivables
85.9m CNY

Based on the financial report for Dec 31, 2025, Shanghai Haohai Biological Technology Co Ltd's Other Receivables amounts to 85.9m CNY.

What is Shanghai Haohai Biological Technology Co Ltd's Other Receivables growth rate?
Other Receivables CAGR 5Y
49%

Over the last year, the Other Receivables growth was 22%. The average annual Other Receivables growth rates for Shanghai Haohai Biological Technology Co Ltd have been 23% over the past three years , 49% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett